Comparative evaluation of H1 receptor blocking activity and safety of newer H1antagonist mizolastine with loratadine and placebo: a randomized double blind three way crossover study

Authors

  • Swarnalatha K. Department of Pharmacology, Kurnool Medical College, Kurnool-518002, India
  • S. Sharon Sonia Department of Pharmacology, Kurnool Medical College, Kurnool-518002, India
  • C. Prabahkar Reddy Department of Pharmacology and Therapeutics, NIMS, Punjagutta, Hyderabad, India
  • Ramesh Kumar Rao Department of Pharmacology and Therapeutics, NIMS, Punjagutta, Hyderabad, India
  • M. U. R Naidu Department of Pharmacology and Therapeutics, NIMS, Punjagutta, Hyderabad, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20161499

Keywords:

Mizolastine, Loratadine, Placebo, Psychometric tests, Histamine prick test.

Abstract

Background: Histamine is a naturally occurring body constituent synthesized from L-histidine by histidine decarboxylase enzyme that is expressed throughout the body including central nervous system neurons, gastric mucosa, mast cells and basophils. The objective of this study was to compare the pharmacological activity and safety of 10 mg mizolastine, 10 mg loratadine and placebo in healthy human volunteers.

Methods: After randomly allocating the 3 drugs, a battery of psychometric tests was done. Histamine prick test for wheal and flare reaction, VAS for sedation and itch followed by salivary flow test were done. Vitals were recorded. The subjects were randomized to receive either of the treatment in a cross-over manner with washout period of 7 days. The wheal and flare areas were recorded before and after 1,2,4,8, and 24 hours.

Results: Mean inhibition on histamine induced wheal and flare response with mizolastine was highly significant as compared to placebo from 1 hour onwards (p<0.001) with maximum inhibition of 98.1±1.8% at 4 hours and of 85.1±24.8percent at 8 hours, for wheal and flare, respectively. The mean inhibition on histamine induced response with loratadine was significant from 2 hours (p<0.05) for wheal area and 1 hour onwards up to 24 hours (P<0.01) for flare area with the maximum inhibition of 56.2±31.6 percent and 60.1±14.2percent at 8hours, respectively. Mean inhibition on histamine induced itch with mizolastine was also significant from 4 hours onwards and persisted up to 24 hours (p<0.05) with maximum inhibition of 58.6±54.2% at 8 hours for the itch response, unlike loratidine. There was no significant change in mean effect on sedation assessed on a VAS of 0-100 mm. There was no significant change in psychomotor functions, salivary flow or vital parameters. All were well tolerated.

Conclusions: Mizolastine has good antihistaminic activity than loratadine. Neither drug causes any psychomotor impairment or has anti-cholinergic action.

References

Estelle F, Simons RMD. Advances in H1 Antihistamines. N Eng J Med. 2004;351(21):2203-17.

Skidgel RA, Erdos EG. Histamine, bradykinin and their antagonists, autacoids, Goodman and Gillman’s The Pharmacological basis of Therapeutics, 11 edition; 629-652.

Feldberg W, Paton DM. The human skin nelicited the tripe response, and therefore concluded histamine release from skin. J of physiology. 1951;114:490-509.

Howarth PH. Assessment of antihistamine efficacy and potency. Clin And Exp Allergy. 1999;29(3):87-97.

Clough G. Experimental models of skin and inflammation. Clin am Exp allergy. 1999;29:105-8.

Takahashi H, Ishida-Yamamoto A, Iizuka H. Effects of bepotastine, cetrizine, fexofenadine and olopatadine on histamine induced wheal and flare response, sedation, and psychomotor performance. Clin and Exp Dermatology. 2004;29(5):526-532.

Simons FER, McMillan JL, Simons KJ. A double-blind single dose, cross over comparision of cetrizine, terfinadine, loratidine, estimazole and chlorpheniramine versus placebo: suppressive effects of histamine- induced wheals and flares during 24 hours in normal subject. J allergy Clin Immunol. 1990;86:540-7.

Grant JA, Danielson L, Rihoux JP, De Vos C. A Double-blind , single dose cross over comparision of cetrizine, ebastine, epinastine, fexofenadine, terfinadine and loratidine versus placebo: suppression of histamine induced wheals and flares during 24 hours in healthy male subjects. Allergy. 1999;54:700-7.

Clough GF, Boutsiouki P, Church MK. Comparision of effects of the levocetrizine and loratidine on histamine induced wheal and flare and itch in human skin. Allergy. 2001;56:985-9.

Danjou P, Molinier P, Berlin I, Patat A, Rosenzweig P, Morselli PL. Assessment of anticholinergic effect of the new antihistamine mizolastine in healthy subjects. Br J Clin Pharmac. 1992;34:328-31.

Bryant CA, Farmer A, Tiplady B. Psychomotor performance investigating the dose response relationship for caffeine and theophylline in elderly volunteers. Eur J of Clin Pharmacol. 1998;15:309-13.

Riedel WJ, Ramaekers JC, Uiterwijk M, O’Hanlon JF. Higher doses of terfinadine and loratidine: acute and subchronic effect on psychomotor and actual driving performance. Institute for drugs, safety and behavior. IGVG. 1990:90-08.

Grant J, Danielson L, Rihoux J, De Vos C. Double blind single dose cross over comparision of cetrizine , evastine, epinastine, fexofenadine, terfinadine and loratidine versus placebo: suppression of histamine induced wheals and flares during 24 hours in healthy male subjects. Allergy. 1999;54:700-7.

Julie A, Dopheide, Glen L. Sleep disorders. Kodakemble Applied therapeutics. 2005;77:12-21.

Curran S, Wattis J. Critical flicker fusion threshold a potentially useful measure for the early detection of alzerhiemers disease. Human psychopharmacology. Clin and Exp. 2001;15:103-12.

Riedel WJ, Van Veggel, O’Hanlon JF. Cetrizine 10 and 20 mg impair psychomotor performance. Clin Exp Allergy. 1990;20(S1):97.

Bradley CM, Nicholson AN. Studies on the central effects of the H1 antagonists loratidine. Eur J Clin Pharmac. 1987;32:419-21.

Pechardre JC, Beudin P, Eschalier A, Trolese JF, Rihoux. A comparision of central and peripheral effects of cetrizine and loratidine. J Int Med Res. 1991;19:285-95.

Patat A, Perault MC, Vandel B, Ulliac N, Zieleniuk I, Rosenzweig P. Lack of interaction between new antihiostamine mizolastine and lorazepam on psychomotor performance and memory in healthy volunteers. Eur J Clin Pharmac. 1995;39:31-8.

Danjou PH, Dunmore C , Curson VH, Rosenzweig P, Hindmarch I, Morselli PL. A double-blind placebo control of study of the psychometric effect of the SL. 85.0324 a new H1 antagonist drug compared to terfinadine and tripolidine in healthy subjects. Eur J Pharmac. 1990;183:534.

Kerr JS, Dunore C, Hindmarch I. A psychomotor and cognitive effects of new antihistamine, mizolastine, comparative terfinadine, triprolidine and placebo in healthy volunteers. Br J Clin Pharmacol. 1994;47:331-5.

Downloads

Published

2016-12-30

How to Cite

K., S., Sonia, S. S., Reddy, C. P., Rao, R. K., & R Naidu, M. U. (2016). Comparative evaluation of H1 receptor blocking activity and safety of newer H1antagonist mizolastine with loratadine and placebo: a randomized double blind three way crossover study. International Journal of Basic & Clinical Pharmacology, 5(3), 661–675. https://doi.org/10.18203/2319-2003.ijbcp20161499

Issue

Section

Original Research Articles